News – Page 945 – Endpoints News

David de Graaf now has his $28.5M launch round in place, building a coenzyme A platform in his latest startup

7 years ago

Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO

7 years ago

Study: Just half of postmarketing commitment trials are published

7 years ago

Right back at you, Pfizer: BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor that could ...

7 years ago

Stepping on Roche's toes, Merck cuts into SCLC niche with third-line Keytruda OK

7 years ago

Sanofi aligns itself with Google to streamline drug development

7 years ago

After watching its share price soar on a Bloomberg report and heated rumors, Biohaven stock takes a billion-dollar ...

7 years ago

Roche fields first approval for Rozlytrek in the run-up to a showdown with Bayer, Pfizer

7 years ago

The top 10 blockbuster drugs in the late-stage pipeline — Evaluate adds 6 new therapies to heavy-hitter list

7 years ago

AstraZeneca/Merck win EU approval for frontline maintenance treatment of ovarian cancer, months after FDA endorsement

7 years ago

AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug

7 years ago

A unicorn stalks Wall Street in search of IPO cash; CASI Pharma in-licenses CD19 therapy from China’s Juventas

7 years ago

Drugmakers sue HHS for trying to add prices to DTC ads

7 years ago

Sanofi Genzyme deserts gene therapy developer Voyager Therapeutics

7 years ago

Investors fret as VBI's hep B vaccine fails key secondary PhIII study goal

7 years ago

As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup

7 years ago

Gene therapy R&D deals turn red hot as Big Pharma steps up to play

7 years ago

Pfizer CEO Albert Bourla is back in the M&A game, but why is he paying $11.4B for Array?

7 years ago

Fueled by early success, Enanta paves way for mid-stage RSV study in adult patients later this year

7 years ago

Philadelphia champions life sciences 'co-working,' reviving former GSK campus in $500M makeover

7 years ago

Cue the M&A chatter: UniQure is scouting for a buyout deal as gene therapy field sizzles — report

7 years ago

Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates

7 years ago

Chi-Med cuts surufatinib PhIII short; FDA greenlights Herceptin copycat from Amgen, Allergan

7 years ago

Tariq Kassum jumps from Obsidian to Celsius helm; Quell Therapeutics taps Iain McGill as new CEO

7 years ago

First page Previous page 942 943 944945946 947 948 Next page Last page